Starting 1 May 2026, China’s General Administration of Customs (GACC) requires export declarations for medical imaging equipment—including CT, DR, and ultrasound systems—to include a newly mandated ‘Restriction Identification Code’ and associated ‘Restriction Declaration Elements’. This change affects exporters targeting emerging markets such as the Middle East and Southeast Asia, particularly for portable ultrasound devices and intraoral scanners incorporating AI algorithms or high-precision sensors.

Event Overview

Effective 1 May 2026, the General Administration of Customs introduced a mandatory requirement for export customs declarations to include a ‘Restriction Identification Code’ and corresponding ‘Restriction Declaration Elements’. The system now automatically verifies whether exported medical imaging equipment falls under dual-use items, China’s Export Control List, or requires overseas medical device registration. Declarations failing to comply with these new fields will result in customs clearance delays.

Industries Affected by Segment

Direct Exporters (Medical Device Manufacturers & Trading Companies)

Manufacturers and trading firms exporting CT, DR, ultrasound, or dental scanning equipment must now embed regulatory classification logic into their export documentation workflows. Non-compliant filings—especially for AI-enabled or sensor-rich devices—trigger automated rejection or manual review, directly impacting shipment timelines and contractual delivery commitments.

Contract Manufacturers & OEM Suppliers

Suppliers producing components or subsystems for final medical imaging devices may be asked to provide upstream compliance documentation (e.g., technical specifications confirming absence of controlled sensors or algorithms). Their role shifts from purely production-focused to supporting traceable, auditable export declarations.

Distribution & Channel Partners (Regional Distributors, Local Representatives)

Distributors handling registration, labeling, or local market authorization for imported devices must now coordinate earlier with exporters to confirm whether products meet destination-country medical device registration requirements—since GACC’s system cross-checks this status pre-clearance.

Key Focus Areas and Practical Response Measures

Monitor official implementation guidance and system updates

GACC has not yet published full technical specifications for the ‘Restriction Identification Code’ generation logic or validation rules. Exporters should track announcements via the GACC website and registered customs broker portals, especially regarding code mapping for specific device categories (e.g., Class II vs. Class III ultrasound).

Prioritize screening for high-risk product categories and destinations

Portable ultrasound units, intraoral scanners, and any imaging devices integrating AI-based image reconstruction or sub-millimeter resolution sensors are explicitly flagged in the notice. Shipments to countries with evolving medical device regulatory frameworks—such as Saudi Arabia, Indonesia, and Vietnam—require enhanced pre-filing verification.

Distinguish between policy signal and operational readiness

The requirement is effective 1 May 2026, but system integration across regional customs offices may vary. Companies should treat early May submissions as test cases—not assume uniform enforcement—and retain records of all submitted codes and validation responses for audit purposes.

Update internal documentation and supplier coordination protocols

Export departments should revise checklists to include mandatory fields for restriction codes and declaration elements. Technical and regulatory teams must jointly define product classifications before filing; procurement teams should request updated compliance statements from component suppliers where sensor or algorithm origin impacts dual-use status.

Editorial Observation / Industry Perspective

Observably, this measure signals a structural shift toward pre-emptive, system-driven export compliance—moving beyond post-submission verification to real-time eligibility screening. Analysis shows it is less a standalone regulatory expansion and more an operationalization of existing controls (e.g., the Dual-Use Items Export Control List and Medical Device Supervision and Administration Regulations) within the customs declaration infrastructure. From an industry perspective, it reflects growing alignment between medical device regulation and broader national export control priorities—particularly where technology convergence (e.g., AI + imaging hardware) blurs traditional classification boundaries. Current enforcement appears focused on documentation integrity rather than substantive re-evaluation of product eligibility; however, sustained attention is warranted as system feedback loops mature.

This update underscores how export compliance is increasingly embedded in product design and supply chain governance—not just logistics execution. It is best understood not as an isolated procedural change, but as an indicator of tightening integration between medical device regulatory status, dual-use classification, and customs automation. Companies treating it solely as a filing checkbox risk operational disruption; those aligning technical documentation, regulatory strategy, and export operations early will better navigate both immediate requirements and future iterations.

Source: General Administration of Customs of the People’s Republic of China (official notice effective 1 May 2026).
Areas requiring ongoing observation: Final technical specifications for ‘Restriction Identification Code’ assignment logic; timeline for full nationwide rollout of automated validation across all ports; potential extensions to other medical device categories beyond imaging equipment.